- Previous Close
153.73 - Open
151.18 - Bid 149.96 x 1000
- Ask 150.26 x 1000
- Day's Range
148.20 - 154.72 - 52 Week Range
125.64 - 179.60 - Volume
860,654 - Avg. Volume
898,591 - Market Cap (intraday)
11.977B - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
13.95 - EPS (TTM)
10.73 - Earnings Date Apr 30, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
164.57
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
www.davita.com76,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DVA
View More
Performance Overview: DVA
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DVA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DVA
View MoreValuation Measures
Market Cap
12.30B
Enterprise Value
23.52B
Trailing P/E
14.33
Forward P/E
13.95
PEG Ratio (5yr expected)
2.11
Price/Sales (ttm)
1.05
Price/Book (mrq)
101.54
Enterprise Value/Revenue
1.84
Enterprise Value/EBITDA
8.63
Financial Highlights
Profitability and Income Statement
Profit Margin
7.31%
Return on Assets (ttm)
7.15%
Return on Equity (ttm)
51.74%
Revenue (ttm)
12.82B
Net Income Avi to Common (ttm)
936.34M
Diluted EPS (ttm)
10.73
Balance Sheet and Cash Flow
Total Cash (mrq)
846M
Total Debt/Equity (mrq)
576.99%
Levered Free Cash Flow (ttm)
1.18B
Research Analysis: DVA
View MoreResearch Reports: DVA
View MoreRaising target price to $160.00
DAVITA INC has an Investment Rating of HOLD; a target price of $160.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $158.00
DAVITA INC has an Investment Rating of HOLD; a target price of $158.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetDaVita's Dialysis Business Is Surrounded by a Narrow Moat
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
RatingPrice TargetRating decreased to a HOLD
DAVITA INC has an Investment Rating of HOLD; a target price of $157.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target